A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical company Gilead Sciences.

The verdict in an unusual patent infringement case marked a defeat for the government and activists who have pushed it to more aggressively assert its financial and legal rights to medicines developed with the help of public funding. The Trump administration brought the lawsuit in 2019 in part because of concern over the high price Gilead was charging.

The legal dispute centered on who devised the idea of […]

See also  Arkansas Nuclear One

By Donato